Highline Wealth Partners LLC Invests $39,000 in CRISPR Therapeutics AG (NASDAQ:CRSP)

Highline Wealth Partners LLC purchased a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 1,000 shares of the company’s stock, valued at approximately $39,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Capital Market Strategies LLC acquired a new stake in shares of CRISPR Therapeutics during the fourth quarter worth $461,000. Capital Advisors Inc. OK raised its holdings in CRISPR Therapeutics by 8.1% during the third quarter. Capital Advisors Inc. OK now owns 300,589 shares of the company’s stock worth $14,122,000 after purchasing an additional 22,583 shares in the last quarter. Geode Capital Management LLC lifted its position in CRISPR Therapeutics by 3.6% in the third quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock valued at $47,383,000 after purchasing an additional 35,196 shares during the period. Granite Bay Wealth Management LLC acquired a new position in CRISPR Therapeutics during the 2nd quarter worth approximately $2,375,000. Finally, State Street Corp boosted its stake in shares of CRISPR Therapeutics by 25.0% in the third quarter. State Street Corp now owns 2,992,988 shares of the company’s stock valued at $140,611,000 after buying an additional 599,304 shares in the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Stock Performance

NASDAQ CRSP traded down $1.73 during trading hours on Friday, hitting $39.56. 1,618,532 shares of the company’s stock were exchanged, compared to its average volume of 1,599,980. CRISPR Therapeutics AG has a 12-month low of $38.20 and a 12-month high of $91.10. The business’s 50 day moving average is $46.39 and its 200-day moving average is $48.83. The firm has a market capitalization of $3.38 billion, a P/E ratio of -13.98 and a beta of 1.68.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.41. The firm had revenue of $0.60 million during the quarter, compared to the consensus estimate of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same period in the previous year, the firm earned ($1.41) earnings per share. As a group, equities research analysts anticipate that CRISPR Therapeutics AG will post -5.13 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on CRSP. Needham & Company LLC restated a “buy” rating and set a $84.00 target price on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Chardan Capital reaffirmed a “buy” rating and issued a $94.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, December 10th. StockNews.com raised CRISPR Therapeutics to a “sell” rating in a research note on Monday, December 30th. JMP Securities reaffirmed a “market outperform” rating and set a $86.00 price objective on shares of CRISPR Therapeutics in a report on Friday, December 20th. Finally, Barclays dropped their price target on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 6th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, CRISPR Therapeutics has a consensus rating of “Hold” and a consensus price target of $78.38.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 4,293 shares of the business’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $198,680.04. Following the transaction, the chief executive officer now owns 226,540 shares in the company, valued at $10,484,271.20. The trade was a 1.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, General Counsel James R. Kasinger sold 1,089 shares of the stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the sale, the general counsel now owns 62,597 shares of the company’s stock, valued at approximately $2,896,989.16. This trade represents a 1.71 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 50,382 shares of company stock valued at $2,744,179. Company insiders own 4.10% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.